Bio-Connect
anti-SARS-CoV-2 Spike Protein S1, mAb (rec.) (blocking) (Covi-1) (preservative free)

anti-SARS-CoV-2 Spike Protein S1, mAb (rec.) (blocking) (Covi-1) (preservative free)

Research Use Only
AG-27B-6005PF
AdipoGen Life Sciences
ApplicationsWestern Blot, ELISA, Neutralisation/Blocking
Product group Antibodies
ReactivityVirus
TargetS
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    anti-SARS-CoV-2 Spike Protein S1 mAb (rec.) (blocking) (Covi-1) (preservative free)
  • Delivery Days Customer
    10
  • Antibody Specificity
    Recognizes and binds to recombinant SARS-CoV-2 Spike Protein S1. It blocks the interaction of SARS-CoV-2 Spike Protein S1 (RBD) to human ACE2. Detects a different epitope as anti-SARS-CoV-2 Spike Protein S1, mAb (rec.) (blocking) (Covi-2) (Prod. No. AG-27
  • Applications
    Western Blot, ELISA, Neutralisation/Blocking
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    Covi-1
  • Concentration
    1 mg/ml
  • Estimated Purity
    >98%
  • Formulation
    Liquid
  • Gene ID43740568
  • Target name
    S
  • Target description
    surface glycoprotein
  • Target synonyms
    GU280_gp02; spike glycoprotein; surface glycoprotein
  • Host
    Human
  • Isotype
    IgG1
  • Protein IDP0DTC2
  • Protein Name
    Spike glycoprotein
  • Scientific Description
    Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome beta-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells. - Recombinant Antibody. Recognizes and binds to recombinant SARS-CoV-2 Spike Protein S1. It blocks the interaction of SARS-CoV-2 Spike Protein S1 (RBD) to human ACE2. Detects a different epitope as anti-SARS-CoV-2 Spike Protein S1, mAb (rec.) (blocking) (Covi-2) (Prod. No. AG-27B-6006PF). Applications: ELISA, FUNC (Blocking), WB. Source: HEK 293 cells. Liquid. In PBS. Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome beta-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 shares 79.5% sequence identity with SARS-CoV and is 96.2% identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells.
  • Reactivity
    Virus
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352203